Jonathan Schatz, M.D., is a Professor of Clinical Medicine and Chair of the CMSR Scientific Advisory Committee in the Division of Hematology at the University of Miami Miller School of Medicine. He began his career as a journalist after graduating from the University of Wisconsin-Madison before pursuing science and medicine. After premedical studies at Brandeis University, he earned his medical degree from the University of Chicago Pritzker School of Medicine, conducting research on blood cancer–related genes in the laboratory of Dr. Harinder Singh. He completed an internal medicine residency at University of Chicago Hospitals and a hematology-oncology fellowship at Memorial Sloan Kettering Cancer Center, where he focused on lymphoma research.
Dr. Schatz began his faculty career at the University of Arizona in 2012, establishing an independent laboratory studying treatment resistance and novel therapies for lymphomas while maintaining an active clinical practice. In 2015, he joined Sylvester Comprehensive Cancer Center at the University of Miami, where his research focuses on overcoming resistance mechanisms to targeted therapies. His work identified PIM kinase–mediated maintenance of cap-dependent translation as a resistance mechanism to mTOR inhibitors and has led to novel therapeutic strategies, including targeting the DEAD-box RNA helicase eIF4A with rocaglates now entering clinical trials.
The Schatz laboratory focuses on diffuse large B-cell lymphoma (DLBCL), exploring novel combination therapies, mechanisms of recurrent oncogenes such as BCL10, and druggable dependencies including Cyclin-G Associated Kinase (GAK). The lab also investigates tumor-intrinsic factors influencing responses to cellular immunotherapies, including CAR T-cell therapies, with ongoing efforts to translate these findings into clinical applications.
